The medications discussed in this article have very different mechanisms of action, but all were designed with one primary goal: to alter the balance between procoagulant and anticoagulant ...

UFH is one of two agents that comprise conventional anticoagulant therapy. It is considered a natural agent and has been the standard of care for many years. Its mechanism of action is depicted in ...

The need for physicians to walk a tightrope between preventing thromboembolic events and causing major bleeds is due to DOACs’ mechanism of action. All existing anticoagulants act on a pathway ...

Now, in our eighth 'Case history' article, Gustafsson and colleagues discuss the discovery of ximelagatran, the first oral anticoagulant with a novel mechanism of action to be developed in half a ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...